Bachem and Jitsubo enter into exclusive Licensing Agreement

(PresseBox) ( Bubendorf/Basel and Yokohama, Japan, )
Bachem (SIX: BANB) and Jitsubo CO., LTD. announce today that they signed an exclusive Licensing Agreement for Jitsubo’s Molecular Hiving™ technology. Under the License agreement, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ technology and transfer these processes to Bachem. Bachem will further optimize, scale up and produce for commercial applications. In return, Jitsubo will receive development fees and royalties.

Using this technology, Bachem expects reduced manufacturing costs, improved sustainability, greener chemistry, efficient scale up, and enhanced in-process controls. The two companies have been establishing a close collaboration and several projects for active pharmaceutical ingredients (APIs) as well as cosmetic peptides, have already been initiated and successfully realized using Jitsubo’s technology at Bachem.

Dr. Günther Loidl, Chief Technology Officer of Bachem Holding AG, comments: “We are convinced that Jitsubo’s Molecular Hiving™ technology offers substantial advantages regarding efficiency, and towards greener manufacturing. It complements Bachem’s current extensive technology base and is a great fit for us because Bachem is already offering unique capabilities in the area of solid phase, hybrid, and solution phase peptide chemistry. We are excited to be the only contract manufacturing organization to offer this innovative technology to our customers.”

Dr. Kazuaki Kanai, Chief Executive Officer of Jitsubo CO., LTD. continues: “It is a great pleasure for us having collaborated with the industry leader, Bachem, in exploring applications of our unique technology, Molecular Hiving™, and now having reached an exclusive License Agreement which will provide opportunities to deliver products to customers much faster and at greater scale. We will continue our development efforts broadening the technology base to meet various requirements from the society and hope to deliver meaningful products to customers through this collaboration and more importantly, to the patients in the world and realize our vision of “Enrich the world with smiles”.

 

About Jitsubo

Jitsubo is a pharmaceutical venture established in 2005 and has developed unique liquid phase peptide manufacturing technology, Molecular Hiving™, which provides low cost, high quality, environment friendly and ease of scale-up for the manufacturing of various peptides. Jitsubo as a research and manufacturing company, has been offering Molecular Hiving™ to global pharmaceutical companies as a contract manufacturer and/or working with CMO. Enrich the world with smiles.

 
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.